A number of new sickle cell disease (SCD) drugs are set to hit the US market, says GlobalData, including gene therapies that could offer patients a cure. The cause of the increase GlobalData notes that one of the gene therapies that is currently closest to entering the market— bluebird bio’s bb1111—is projected to represent over […]
